The durability of the immunity is the biggest concern we heard—also even with a booster. When is the next booster? In addition, one option is spacing the booster a little farther—especially for younger cohorts and/or people with prior infections: aka front-loading the supply.
I’m happy to engage, but the one part that think most about is the public sphere. So the question you raise—and it’s penumbra—is the one I actually think most about, and has had most of my career focused around. I’m not new to that part at all. The immunology is for the experts.
-
-
We are not spreading a dangerous idea, we’re taking one with a real upside and trying to put it on a solid path. Do you notice how many prominent politicians had been advocating for this? It’s not a world where we can somehow keep things quiet—or control them without being there.
-
The question I’ve asked is whether boosting this idea in the NYT and elsewhere as opposed to working behind the scenes to develop a trial has potential downsides. All I hear from you and Michael is that this approach has no risks.
- Show replies
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.